In classical Hodgkin lymphoma, the activity of Thymidine kinase-1 is not related to tumor size
Abstract
Introduction: Classical Hodgkin lymphoma (cHL), a common lymphatic malignancy commonly occurring in people aged between 30 and 40, is known to have serum thymidine kinase 1 (TK1) as a confirmed diagnostic marker. However, the relationship between serum TK1 and tumor volume is controversial.
Objectives: Examination of the relationship between serum TK1 activity and lymph node volume in patients with cHL.
Materials and methods: Twenty-four patients with HL underwent PET/CT examinations, and a control group of 30 healthy subjects was established. PET / CT scans were analyzed to determine the maximum standardized uptake value (SUVmax), tumor size, and volume. Serum TK1 levels were measured using the DiaSorin LIAISON assay.
Results: The findings demonstrated a high serum TK1 concentration in cHL patients and further validated TK1 serum as a diagnostic biomarker. However, no statistically significant association was observed between serum TK1 activity and lymph node size. These results suggest that although serum TK1 is a useful diagnostic marker for cHL, Serum TK1 is unreliable for measuring tumor aggressiveness and malignancy.
Conclusions: This study offers new data on the biology of cHL and highlights the importance of continuing research on alternative biomarkers for disease surveillance and prediction.
Keywords: classical Hodgkin lymphomathymidine kinase 1marker
References
- Küppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol. 2005; 37(3): 511–517.
- Benharroch D, Zarin P, Nalbandyan K. The CD15 Immunohistochemical Marker of Hodgkin-Reed-Sternberg cells - a Perspective. BJSTR. 2018; 3(3).
- Wedgwood A, Younes A. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy. Clin Adv Hematol Oncol. 2014; 12(4 Suppl 10): 1–22.
- Singh R, Shaik S, Negi BS, et al. Non-Hodgkin's lymphoma: A review. J Family Med Prim Care. 2020; 9(4): 1834–1840.
- Thandra KC, Barsouk A, Saginala K, et al. Epidemiology of non-Hodgkin's lymphoma. Med Sci (Basel). 2021; 9(1).
- Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016; 127(20): 2375–2390.
- Maggioncalda A, Malik N, Shenoy P, et al. Clinical, molecular, and environmental risk factors for Hodgkin lymphoma. Adv Hematol. 2011; 2011: 736261.
- Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000; 343(7): 481–492.
- Agostinelli C, Pileri S. Pathobiology of Hodgkin lymphoma. Mediterr J Hematol Infect Dis. 2014; 6(1): e2014040.
- Chang ET, Smedby KE, Hjalgrim H, et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst. 2005; 97(19): 1466–1474.
- Jacobson CA, Abramson JS. HIV-Associated hodgkin's lymphoma: prognosis and therapy in the era of cART. Adv Hematol. 2012; 2012: 507257.
- Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clin Lymphoma Myeloma. 2009; 9(3): 206–216.
- Sun R, Medeiros LJ, Young KH. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016; 29(10): 1118–1142.
- Fernández-Vega I, Quirós LM, Santos-Juanes J, et al. Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma. Virchows Arch. 2015; 466(2): 229–235.
- de Oliveira KAP, Kaergel E, Heinig M, et al. A roadmap of constitutive NF-κB activity in Hodgkin lymphoma: Dominant roles of p50 and p52 revealed by genome-wide analyses. Genome Med. 2016; 8(1): 28.
- Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007; 109(7): 2700–2707.
- Tzankov A, Dirnhofer S. Pathobiology of classical Hodgkin lymphoma. Pathobiology. 2006; 73(3): 107–125.
- Mattsson Ulfstedt J, Venge P, Holmgren S, et al. Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma. Ups J Med Sci. 2021; 126.
- Eriksson B, Hagberg H, Glimelius B, et al. Serum thymidine kinase as a prognostic marker in Hodgkin's disease. Acta Radiol Oncol. 1985; 24(2): 167–171.
- He E, Xu XH, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids. 2010; 29(4-6): 352–358.
- Aufderklamm S, Todenhöfer T, Gakis G, et al. Thymidine kinase and cancer monitoring. Cancer Lett. 2012; 316(1): 6–10.
- Chen ZH, Huang SQ, Wang Y, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours--a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel). 2011; 11(12): 11064–11080.
- Larsson AM, Bendahl PO, Aaltonen K, et al. Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer. Sci Rep. 2020; 10(1): 4484.
- Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009; 9(1): 15–27.
- Topolcan O, Holubec L. The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn. 2008; 2(2): 129–141.
- Gatt M, Goldschmidt N, Kalichman I, et al. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation. Anticancer Res. 2015; 35(5): 3019–3026.